Financial Instruments - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Jan. 31, 2025
Derivative [Line Items]
Total Swap Notional Amount	$ 38,560	$ 30,551
Pretax net unrealized losses on derivatives maturing within the next 12 months estimated to be reclassified from AOCI to sales	(262)
Equity investments without readily determinable fair values	863	832
Unrealized gains recognized on investments in equity securities without readily determinable fair value	19	10
Unrealized losses recognized on investments in equity securities without readily determinable fair values	51	61
Cumulative upward price adjustment	309
Cumulative downward price adjustment	107
(Income) loss from investments in equity securities, net	(14)	(340)	$ 1,419
Payments of contingent consideration	151	117
Fair value of loans payable and long-term debt, including current portion	32,600	32,000
Debt, carrying amount	37,100	35,100
Factored accounts receivable	2,100	3,000
Cash collateral received from counterparties	$ 165	3
5.00% notes due 2053
Derivative [Line Items]
Stated interest rate	5.00%
Senior Notes | Subsequent Event | 5.00% notes due 2053
Derivative [Line Items]
Stated interest rate				5.00%
Interest rate swap contracts | 5.00% notes due 2053 | Subsequent Event
Derivative [Line Items]
Total Swap Notional Amount				$ 250
Lyfnua
Derivative [Line Items]
Payments of contingent consideration	$ 25
Sanofi Pasteur
Derivative [Line Items]
Payments of contingent consideration	126
Equity Funds
Derivative [Line Items]
Equity securities held through ownership interests in investment funds	267	417	598
(Income) loss from investments in equity securities, net	29	106	$ 1,000
Accounts Receivable Factoring Collections
Derivative [Line Items]
Funds collected from factoring of receivable, held in restricted cash	$ 55	44
Customer Concentration Risk | Accounts Receivable | McKesson Corporation
Derivative [Line Items]
Percentage of accounts receivable represented by customers with largest balances	21.00%
Customer Concentration Risk | Accounts Receivable | Cencora, Inc.
Derivative [Line Items]
Percentage of accounts receivable represented by customers with largest balances	21.00%
Customer Concentration Risk | Accounts Receivable | Cardinal Health, Inc.
Derivative [Line Items]
Percentage of accounts receivable represented by customers with largest balances	13.00%
Level 2
Derivative [Line Items]
Cash equivalents	$ 12,300	6,000
Derivatives Designated as Hedging Instruments
Derivative [Line Items]
Total Swap Notional Amount	12,465	12,754
Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Total Swap Notional Amount	$ 26,095	$ 17,797
Maximum | Derivatives Designated as Hedging Instruments
Derivative [Line Items]
Term of derivative contract	2 years
Maximum | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Maximum planning cycle of hedges (less than)	6 months